BG104432A - Терапевтично използване на хинолинови производни - Google Patents
Терапевтично използване на хинолинови производни Download PDFInfo
- Publication number
- BG104432A BG104432A BG104432A BG10443200A BG104432A BG 104432 A BG104432 A BG 104432A BG 104432 A BG104432 A BG 104432A BG 10443200 A BG10443200 A BG 10443200A BG 104432 A BG104432 A BG 104432A
- Authority
- BG
- Bulgaria
- Prior art keywords
- quinolinylmethyloxy
- compound
- alkyl
- tetrazole
- phenoxymethyl
- Prior art date
Links
- 0 *CNC(Cc1cccc(COC(C2)C=CC=C2OCC2N=C(C=CC=C3)C3=CC2)c1)=N Chemical compound *CNC(Cc1cccc(COC(C2)C=CC=C2OCC2N=C(C=CC=C3)C3=CC2)c1)=N 0.000 description 3
- AWHSQBQAQBXRMH-UHFFFAOYSA-N C(c(cc1)ccc1-c1nnn[nH]1)Oc1cccc(OCc2nc3ccccc3cc2)c1 Chemical compound C(c(cc1)ccc1-c1nnn[nH]1)Oc1cccc(OCc2nc3ccccc3cc2)c1 AWHSQBQAQBXRMH-UHFFFAOYSA-N 0.000 description 1
- KSLJQZMWPJNKKP-UHFFFAOYSA-O C(c(cc1)ccc1OCc1nc2ccccc2cc1)Oc(cc1)ccc1-c1n[nH+]n[nH]1 Chemical compound C(c(cc1)ccc1OCc1nc2ccccc2cc1)Oc(cc1)ccc1-c1n[nH+]n[nH]1 KSLJQZMWPJNKKP-UHFFFAOYSA-O 0.000 description 1
- KOXHPVHOZNZZSJ-UHFFFAOYSA-N C(c1cc(OCc2nc3ccccc3cc2)ccc1)Oc1cccc(-c2nnn[nH]2)c1 Chemical compound C(c1cc(OCc2nc3ccccc3cc2)ccc1)Oc1cccc(-c2nnn[nH]2)c1 KOXHPVHOZNZZSJ-UHFFFAOYSA-N 0.000 description 1
- WLGCQGMQMAOULL-UHFFFAOYSA-N C(c1cccc(-c2nnn[nH]2)c1)Oc1cc(OCc2nc3ccccc3cc2)ccc1 Chemical compound C(c1cccc(-c2nnn[nH]2)c1)Oc1cc(OCc2nc3ccccc3cc2)ccc1 WLGCQGMQMAOULL-UHFFFAOYSA-N 0.000 description 1
- LRHAGGWPAYKDOL-UHFFFAOYSA-N C(c1nnn[nH]1)Oc1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)cc1 Chemical compound C(c1nnn[nH]1)Oc1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)cc1 LRHAGGWPAYKDOL-UHFFFAOYSA-N 0.000 description 1
- SSPUCOWJOYUIGO-UHFFFAOYSA-N COC(c1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)c(OCc2nnn[nH]2)c1)=O Chemical compound COC(c1ccc(COc2cccc(OCc3nc4ccccc4cc3)c2)c(OCc2nnn[nH]2)c1)=O SSPUCOWJOYUIGO-UHFFFAOYSA-N 0.000 description 1
- PTSDFSPWBZHXMQ-UHFFFAOYSA-N OC(COc(c(COc1cc(OCc2nc3ccccc3cc2)ccc1)ccc1)c1Cl)=O Chemical compound OC(COc(c(COc1cc(OCc2nc3ccccc3cc2)ccc1)ccc1)c1Cl)=O PTSDFSPWBZHXMQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6231897P | 1997-10-17 | 1997-10-17 | |
| US6590297P | 1997-11-17 | 1997-11-17 | |
| PCT/US1998/021947 WO1999020275A1 (en) | 1997-10-17 | 1998-10-16 | Therapeutic uses of quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104432A true BG104432A (bg) | 2000-12-29 |
Family
ID=26742119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104432A BG104432A (bg) | 1997-10-17 | 2000-05-15 | Терапевтично използване на хинолинови производни |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6376512B1 (de) |
| EP (1) | EP1030665A4 (de) |
| JP (1) | JP2001520193A (de) |
| KR (1) | KR20010024533A (de) |
| CN (1) | CN1302206A (de) |
| AP (1) | AP2000001786A0 (de) |
| AU (1) | AU9696198A (de) |
| BG (1) | BG104432A (de) |
| BR (1) | BR9814087A (de) |
| CA (1) | CA2306825A1 (de) |
| EA (1) | EA200000427A1 (de) |
| HU (1) | HUP0101022A1 (de) |
| IL (1) | IL135673A0 (de) |
| NO (2) | NO20001962L (de) |
| OA (1) | OA11371A (de) |
| PL (1) | PL344977A1 (de) |
| WO (1) | WO1999020275A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4598278B2 (ja) | 1999-04-28 | 2010-12-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体 |
| SK15522001A3 (sk) * | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| CA2382966A1 (en) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| JP2001261654A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| AU6118001A (en) * | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| DE60139025D1 (de) | 2000-12-28 | 2009-07-30 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| NZ530051A (en) * | 2001-06-12 | 2006-12-22 | Wellstat Therapeutics Corp | Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders |
| JPWO2003016265A1 (ja) * | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびｐｐａｒアゴニスト |
| ES2299702T3 (es) | 2002-06-20 | 2008-06-01 | Astrazeneca Ab | Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina. |
| SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| WO2005026134A1 (en) | 2003-09-17 | 2005-03-24 | Novartis Ag | Organic compounds |
| JP2007536343A (ja) | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体 |
| EP1745014B1 (de) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Neue verbindungen, deren herstellung und verwendung |
| CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
| ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
| TW200800872A (en) * | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
| EA015717B1 (ru) | 2005-12-22 | 2011-10-31 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
| EP1999098A2 (de) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung |
| US9308198B2 (en) | 2006-09-08 | 2016-04-12 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| US7645616B2 (en) * | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
| US8410154B2 (en) | 2008-04-30 | 2013-04-02 | Wellstat Therapeutics Corporation | Tetrazole compounds for reducing uric acid |
| JP5785940B2 (ja) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス， エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
| KR20120026612A (ko) | 2009-06-09 | 2012-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 벤질 치환 트리아진 유도체와 이들의 치료적 용도 |
| AU2010258800B2 (en) | 2009-06-09 | 2013-10-10 | Nantbio, Inc. | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| EP2590951B1 (de) | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzolsulfonamide als kaliumkanalhemmer |
| WO2012007877A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| ES2525581T3 (es) | 2010-07-12 | 2014-12-26 | Pfizer Limited | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje |
| US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
| WO2012007869A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| EP3129345B1 (de) * | 2014-04-06 | 2023-03-15 | Sanford-Burnham Medical Research Institute | Metabotrope glutamatrezeptor-positive allosterische modulatoren (pams) und verwendungen davon |
| US20230357159A1 (en) * | 2020-08-04 | 2023-11-09 | Precision Bio-Therapeutics S.R.L. | Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US4920130A (en) * | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| AU683114B2 (en) * | 1993-11-29 | 1997-10-30 | Merrell Pharmaceuticals Inc. | Novel benzenesulfonylimine derivatives as inhibitors of IL-1 action |
| DE69512495T2 (de) * | 1994-10-27 | 2000-02-03 | Asahi Glass Co. Ltd., Tokio/Tokyo | Verfahren zur Herstellung von Chinolin-2-yl-benzoesäure |
| PT871439E (pt) * | 1996-01-02 | 2004-08-31 | Aventis Pharma Inc | Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo) |
-
1998
- 1998-10-16 CA CA002306825A patent/CA2306825A1/en not_active Abandoned
- 1998-10-16 EA EA200000427A patent/EA200000427A1/ru unknown
- 1998-10-16 HU HU0101022A patent/HUP0101022A1/hu unknown
- 1998-10-16 BR BR9814087-6A patent/BR9814087A/pt not_active Application Discontinuation
- 1998-10-16 EP EP98951075A patent/EP1030665A4/de not_active Withdrawn
- 1998-10-16 JP JP2000516672A patent/JP2001520193A/ja active Pending
- 1998-10-16 PL PL98344977A patent/PL344977A1/xx unknown
- 1998-10-16 KR KR1020007004131A patent/KR20010024533A/ko not_active Application Discontinuation
- 1998-10-16 CN CN98811303A patent/CN1302206A/zh active Pending
- 1998-10-16 AU AU96961/98A patent/AU9696198A/en not_active Abandoned
- 1998-10-16 WO PCT/US1998/021947 patent/WO1999020275A1/en not_active Application Discontinuation
- 1998-10-16 IL IL13567398A patent/IL135673A0/xx unknown
-
2000
- 2000-01-27 US US09/490,897 patent/US6376512B1/en not_active Expired - Fee Related
- 2000-04-07 AP APAP/P/2000/001786A patent/AP2000001786A0/en unknown
- 2000-04-13 OA OA1200000106A patent/OA11371A/en unknown
- 2000-04-14 NO NO20001962A patent/NO20001962L/no not_active Application Discontinuation
- 2000-05-15 BG BG104432A patent/BG104432A/bg unknown
- 2000-06-16 NO NO20003107A patent/NO20003107L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU9696198A (en) | 1999-05-10 |
| HUP0101022A1 (hu) | 2001-10-28 |
| NO20003107L (no) | 2000-07-26 |
| AP2000001786A0 (en) | 2000-04-16 |
| EP1030665A1 (de) | 2000-08-30 |
| IL135673A0 (en) | 2001-05-20 |
| OA11371A (en) | 2004-01-28 |
| CA2306825A1 (en) | 1999-04-29 |
| NO20001962L (no) | 2000-06-16 |
| BR9814087A (pt) | 2000-10-03 |
| NO20003107D0 (no) | 2000-06-16 |
| EP1030665A4 (de) | 2002-11-27 |
| PL344977A1 (en) | 2001-11-19 |
| CN1302206A (zh) | 2001-07-04 |
| KR20010024533A (ko) | 2001-03-26 |
| NO20001962D0 (no) | 2000-04-14 |
| EA200000427A1 (ru) | 2001-02-26 |
| US6376512B1 (en) | 2002-04-23 |
| WO1999020275A1 (en) | 1999-04-29 |
| JP2001520193A (ja) | 2001-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG104432A (bg) | Терапевтично използване на хинолинови производни | |
| US20030220373A1 (en) | Therapeutic uses of PPAR mediators | |
| TW584560B (en) | Pharmaceutical composition of substituted indolealkanoic acids for reducing serum glucose and triglyceride levels and inhibiting angiogenesis | |
| KR100709498B1 (ko) | Ｐｐａｒ 수용체 리간드로서의 디아릴 산 유도체 | |
| JP2003525217A (ja) | 肥満治療用薬剤 | |
| CN101268060A (zh) | 噻唑啉酮和噁唑啉酮类化合物及其作为ptp1b抑制剂的应用 | |
| US20210047337A1 (en) | Triazolopyrimidines, their preparation and use | |
| TW200803896A (en) | Method of improvement of cognitive function | |
| BRPI0615046B1 (pt) | uso de um composto | |
| CN101948416A (zh) | 用于治疗代谢紊乱的化合物 | |
| EP1572180B1 (de) | Verwendung von alpha-phenylthiokarbonsäuren mit serumglucose- und serumlipid-senkender wirkung | |
| WO2004093910A1 (ja) | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 | |
| US10377695B2 (en) | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | |
| WO2021032218A1 (zh) | 一种并环THRβ受体激动剂化合物及其制备方法和用途 | |
| AU2007257854B2 (en) | Compounds for the treatment of metabolic disorders | |
| JP2000500490A (ja) | 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド | |
| TW201818964A (zh) | 使用色胺酸羥化酶抑制劑之方法 | |
| CN108299411B (zh) | 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途 | |
| ZA200506257B (en) | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
| JPH09505081A (ja) | ５−リポキシゲナーゼ阻害物質としてのイソキサゾリン化合物 |